Document Detail


Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy.
MedLine Citation:
PMID:  21562407     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
It has been proposed that thioredoxin reductase (TR) is a mediator that allows non-small cell lung cancer (NSCLC) to develop resistance to irradiation; however, little is known regarding the detailed mechanisms of action. Thus, ethaselen {1, 2-[bis (1,2-benzisoselenazolone-3 (2H)-ketone)] ethane, BBSKE}, a novel organoselenium TR inhibitor, is currently being investigated in a phase I clinical trial in China. However, its radiosensitizing effect remains unexplored. In this study, we found that the activity of TR increased dramatically in both A549 and H1299 cells after radiation, and moreover, could be inhibited by pretreatment with BBSKE (5 μmol/l). As a TR inhibitor, BBSKE enhanced the efficacy of radiation therapy both in vivo and in vitro without observable toxicity. BBSKE was found to suppress irradiation-induced NF-κB activation dramatically when using A549 cells stably transfected with NF-κB luciferase reporter. These results show the critical role of TR in the radioresistance of NSCLC and suggest that BBSKE is a potentially promising agent for the treatment of patients with NSCLC clinically.
Authors:
Lei Wang; Jia-Ning Fu; Jing-Yu Wang; Cun-Jing Jin; Xiao-Yuan Ren; Qiang Tan; Jing Li; Han-Wei Yin; Kun Xiong; Tian-Yu Wang; Xin-Min Liu; Hui-Hui Zeng
Related Documents :
19020747 - Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fi...
9556187 - Phorbol esters: useful tools to study megakaryocyte differentiation.
3986807 - Cutaneous changes during prolonged application of 12-o-tetradecanoylphorbol-13-acetate ...
7273307 - Tumor promoter inhibition of intercellular communication between cultured mammalian cells.
24044367 - A synthetic curcumin derivative hydrazinobenzoylcurcumin induces autophagy in a549 lung...
20923857 - Identification of predictive markers of response to the mek1/2 inhibitor selumetinib (a...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-10
Journal Detail:
Title:  Anti-cancer drugs     Volume:  -     ISSN:  1473-5741     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
aPeking University First Hospital bState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences cCollege of Life Sciences, Peking University dSchool of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clarification of clinical features of interstitial lung disease induced by irinotecan based on postm...
Next Document:  Antinociceptive activity of (-)-(2S,6S)-(6-ethyl-tetrahydropyran-2-yl)-formic acid on acute pain in ...